Sign-in to Ask A Doctor - 24x7
OR
Sign in with Google
Does Chemotherapy Help In Treating Oncotype Breast Cancer?
Question: If a breast cancer patient has bilateral tumors, is ER/PR+, HER2-, Grade 1, 2cm XXXXXXX and has an oncotypeDX score of 13, should she have chemotherapy?
Brief Answer:
not much role of chemo
Detailed Answer:
Hi
Thanks for your query.
These appear to be low risk tumors as per the size, grade, receptor status and oncotype scores. So, chemotherapy hardly provides any benefit. Only risk factor is the presence of two positive lymph nodes. But recent data shows that oncotype score predicts even in 1-3 node positive patients.
If you give chemo, in this patient the benefit in risk reduction may be around 2%, which is too low. Hence, I would not recommend chemotherapy.
Hope this helps.
Regards
not much role of chemo
Detailed Answer:
Hi
Thanks for your query.
These appear to be low risk tumors as per the size, grade, receptor status and oncotype scores. So, chemotherapy hardly provides any benefit. Only risk factor is the presence of two positive lymph nodes. But recent data shows that oncotype score predicts even in 1-3 node positive patients.
If you give chemo, in this patient the benefit in risk reduction may be around 2%, which is too low. Hence, I would not recommend chemotherapy.
Hope this helps.
Regards
Above answer was peer-reviewed by :
Dr. Prasad
Thank you, Dr. XXXXXXX Your answer is consistent with NCCN and research results on Genomic Health's website. Unfortunately, the patient received four cycles of TC. Reduced from dose-dense AC-T once the recurrence score was reported. I'm not an MD, but a friend of the patient and CEO of PatientWithPower. Your recommendation is the same I got from other sources. I appreciate your reply.
Brief Answer:
difference in practice exists
Detailed Answer:
Some doctors and centers have not yet adopted oncotype dx fully in node positive patients. They are waiting for the results of the prospective study RxPONDER to come out. So difference in opinion is common.
difference in practice exists
Detailed Answer:
Some doctors and centers have not yet adopted oncotype dx fully in node positive patients. They are waiting for the results of the prospective study RxPONDER to come out. So difference in opinion is common.
Above answer was peer-reviewed by :
Dr. Sonia Raina
Understandable that doubts about Genomic Health's results are questioned, as the sample size was very small in the node positive study. Per your advice, I'll track the RxPONDER trial for future guidance. Thank you for your additional feedback.
Brief Answer:
sure
Detailed Answer:
If you have no other queries, then please close this query and give feedback
sure
Detailed Answer:
If you have no other queries, then please close this query and give feedback
Note: For further queries related to kidney problems Click here.
Above answer was peer-reviewed by :
Dr. Prasad
Answered by
Get personalised answers from verified doctor in minutes across 80+ specialties
